For decades, CNS diseases have imposed significant physical and mental burdens on affected individuals. With over 95% of CNS diseases having unknown causes, scientists face substantial challenges in developing effective treatments. Parkinson’s disease and Alzheimer’s disease are among the most prevalent CNS conditions, and despite extensive research, the complexity of the brain has limited our findings. However, recent studies have introduced promising breakthroughs for these disorders.

Researchers at the Salk Institute recently published a paper in Cell Stem Cell highlighting that Alzheimer’s disease involves the degeneration of neurons and a late-life stress process known as senescence. These deteriorating neurons release inflammatory factors that initiate a cascade of brain inflammation, disrupting other brain cells. This research suggests that targeting senescent cells could be a viable strategy to slow neuroinflammation and neurodegeneration in Alzheimer’s disease. Additionally, some existing drugs that cross the blood-brain barrier (BBB) might become future treatment options, offering hope and representing a significant advancement in Alzheimer’s disease therapy.

In parallel, scientists from the UK and Sweden are developing a new potential therapy for Parkinson’s disease. Their approach involves using lab-grown nerve cells transformed from stem cells to replace those damaged by the disease. This method aims to halt the progression of debilitating symptoms by transplanting dopaminergic neurons into the midbrain. Given the substantial loss of dopamine neurons in the substantia nigra pars compacta and decreased innervation to the striatum in Parkinson’s disease, this technique is viewed as a promising therapeutic strategy. The differentiation of dopaminergic neurons is gaining attention as a critical area of research, though further studies are needed for successful clinical application.

Creative Biolabs, a pioneering biotech CRO specializing in neurological models, offers a comprehensive technology platform supported by advanced facilities, expert teams, and cutting-edge technologies. The company is committed to providing global customers with a range of neuroscience services and research tools, including custom dopaminergic neuron differentiation models, to accelerate progress in neuroscience research.